Cromolyn Sodium for Treatment of COVID-19 Pneumonia
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will
improve patient symptoms and reduce the number of days to improved quality of life.
Investigators will study the effects of adding cromolyn to the standard treatment of
hospitalized patients with COVID-19 pneumonia and who require supplemental oxygen. Cromolyn
will be administered as a nebulized treatment four times a day for four days followed by
intranasal administration for two weeks. Investigators may also screen for biomarkers that
could indicate inflammatory responses and treatment-induced improvement.
Participants will receive either study drug or placebo which will be administered by
nebulization for 4 days followed by 14 days of intranasal administration. Participants will
be followed while in the hospital and then as outpatients up to day 21 following
randomization.
Phase:
Phase 3
Details
Lead Sponsor:
Texas Tech University Health Sciences Center, El Paso